Adapted by Steven Hoover from the 9/24/2010 EmaxHealth posting by Deborah Mitchell Researchers are one step closer to discovering the genetic precursors to lateonset Alzheimer’s disease, the most common type of the disease. Investigators from four institutions, including Dr. Joseph Buxbaum of Mount Sinai Medical Center, collaborated to discover the role of variations in a […]
Over the past 25 years there have been few changes in the diagnosis of Alzheimer disease (AD) even though our knowledge of the disease and its progression has grown. For example, the current criteria have age cutoffs (between 40 and 90 years of age), but we know now that many people living into their 90’s […]
From October 12, 2010 MSSM Press Release Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer’s disease. The research, led by Giulio Maria Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of […]
From “Mount Sinai Press Release,” dated 4/27/10 A recent study published in April 2010 in the Annals of Neurology suggests that the prevailing theory of sticky amyloid plaques as the cause to Alzheimer’s disease may in fact be wrong. New research by Sam Gandy, M.D., Ph.D., the Associate Director of the Mount Sinai Alzheimer’s Disease […]
The first evidence of a link between history of head injury and risk for developing Alzheimer’s disease (AD) was a case report of AD pathology in the brain of a 38 year-old man who had suf- fered a single episode of a head injury 16 years earlier. This finding lead to the idea that head […]
Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer’s disease.
Congratulations to George Marzloff, one of our ADRC research coordinators, who was recently published in the January 2009 issue of Developmental Neuroscience. While pursuing his undergraduate degree, George and other researchers from the Massachusetts Institute of Technology investigated the effects of supplementing rat mothers with uridine and docosahexaenoic acid (DHA) on the brains of rat […]
The results of Dr. Mitsis’s study indicate that patients with AD and MCI with and without depression share a common decrease in relative glucose activity in the temporal and parietal lobes. These are the regions of the brain that are typically affected in AD. In contrast, in the frontal lobe of the brain, a disassociation was seen with increased activity in the AD group in regions of the frontal lobe that possibly represents compensatory activation. However, patients with MCI and depression did not show this compensatory activity but instead showed a decrease, such as that often reported in mood disorders.
“This US Phase II trial has clearly demonstrated efficacy of Huperzine A in the treatment of AD. Completion of the planned analyses, including examination of drug levels and cholinesterase inhibition, will be valuable in the design of further studies.”